Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ADCY10 | Q96PN6 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1319082 | 0.84 | SMN1; SMN2 (0.68) | HRH4SMN1; SMN2APPCYP2D6CYP2C19 | |
| SCHEMBL18177428 | 0.80 | APP (0.57) | HRH4SMN1; SMN2APPCYP2D6ADCY10 | |
| SCHEMBL1192209 | 0.78 | NTRK1 (0.49) | HRH4APPCCNT1KDM5AKDM4C | |
| SCHEMBL1191942 | 0.78 | KCNN3 (0.53) | HRH4APPCCNT1KDM5AKDM4C | |
| SCHEMBL12466337 | 0.77 | CCNT1 (0.57) | CCNT1CYP2D6CYP2C19KDM5AKDM4C | |
| SCHEMBL18636741 | 0.76 | HRH4 (0.80) | HRH4SMN1; SMN2APP | |
| SCHEMBL1192525 | 0.76 | BRAF (0.53) | CCNT1KDM5AKDM4CKDM5B | |
| SCHEMBL9475118 | 0.76 | OPRK1 (0.60) | HRH4SMN1; SMN2CYP2D6CYP2C19ADCY10 | |
| SCHEMBL18177427 | 0.76 | HRH4 (0.63) | HRH4SMN1; SMN2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL12605070 | 0.74 | HRH4 (0.78) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HRH4 184/4885SMN1; SMN2 1788/4885APP 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.